Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 90

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 90
---
 laws in the United States. Consequently, we may not be able to prevent third parties from
utilizing our inventions in all countries outside the United States, even in jurisdictions where we do pursue patent protection.
Competitors may use our technologies in jurisdictions where we have not pursued and obtained patent protection to develop their
own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement
is not as strong as that in the United States. These products may compete with our compounds, and our patents or other intellectual
property rights may not be effective or sufficient to prevent them from competing.

Many
companies have encountered significant problems in protecting intellectual property and enforcing intellectual property rights
in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the
enforcement of patents, trade secrets and other intellectual property protections, particularly those relating to biotechnology
products and those of foreign entities. Such challenges in enforcing rights in these countries could make it difficult for us
to stop the infringement of our patents, if pursued and obtained, or marketing of competing products in violation of our proprietary
rights generally. Proceedings to enforce our current and future patent rights in foreign jurisdictions could result in substantial
costs and may divert our efforts and attention from other aspects of our business; could put our asserted patents at risk of being
invalidated or interpreted narrowly; could put any future patent applications, including continuation and divisional applications,
at risk of not issuing; and could provoke third parties to assert their own patent claims against us or to attack the validity
of our other patents. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any,
may not be commercially meaningful. Accordingly, our efforts to enforce any intellectual property rights around the world stemming
from intellectual property that we develop may be inadequate to obtain a significant commercial advantage in these foreign jurisdictions.

52 

Third
parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which
would be uncertain and could have a material adverse effect on the success of our business. 

Our
commercial success depends upon our ability (and the ability of any potential future collaborators) to develop, manufacture, market
and sell CC8464, CT2000, CT3000 and future new compounds, and to freely use our proprietary technologies (e.g., without
infringing the intellectual property rights of others). Many companies and institutions have filed, and continue to file, patent